Guardant Health, Inc. - Common Stock (NQ:GH)

105.30 +2.54 (+2.47%)

Streaming Delayed Price Updated: 10:04 AM EST, Feb 13, 2026 Add to My Watchlist

Price and Volume

Volume	81,458
Open	102.90
Bid (Size)	104.50 (200)
Ask (Size)	105.69 (200)
Prev. Close	102.76
Today's Range	102.75 - 105.70
52wk Range	34.88 - 120.74
Shares Outstanding	101,298,669
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Guardant Health to Participate in Upcoming Investor Conferences

February 03, 2026

From Guardant Health, Inc.

Via Business Wire

Largest Published Study of Molecular Residual Disease (MRD) in Stage III Colon Cancer Shows Guardant Reveal Blood Test More Precisely Identifies Risk of Recurrence After Surgery to Support Timely Treatment Decisions

February 02, 2026

From Guardant Health, Inc.

Via Business Wire

Performance

YTD	+3.5%	+3.5%
1 Month	-1.5%	-1.5%
3 Month	+11.9%	+11.9%
6 Month	+74.5%	+74.5%
1 Year	+132.0%	+132.0%

More News

3 Unpopular Stocks We Think Twice About

February 01, 2026

Via StockStory

Should You Buy Guardant Health Before Feb. 19? ↗

January 30, 2026

Via The Motley Fool

Guardant Health to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026

January 29, 2026

From Guardant Health, Inc.

Via Business Wire

Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for BRAFTOVI® (encorafenib) Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer

January 22, 2026

From Guardant Health, Inc.

Via Business Wire

Guardant Health Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform

January 19, 2026

From Guardant Health, Inc.

Via Business Wire

Guardant Health (NASDAQ:GH): Strongest Q3 Results from the Testing & Diagnostics Services Group

January 14, 2026

Via StockStory

CS Diagnostics (OTCQB: CSDX) Advances Infection Control and Oncology Innovation Plus – IVP, SAFX, JTAI, OCG, BMXI Inside

January 14, 2026

Via AB Newswire

GRAIL Surges as Canaccord Genuity Sets Ambitious $105 Price Target Following Robust 2025 Growth

January 13, 2026

Via MarketMinute

Adaptive Biotechnologies Surges as Preliminary 2025 Results Signal a Turning Point in MRD Commercialization

January 13, 2026

Via MarketMinute

Biodesix Shares Rocket 42% on Record FY2025 Results and Path to Profitability

January 12, 2026

Via MarketMinute

Guardant Health Announces Preliminary Fourth Quarter and Full Year 2025 Results

January 11, 2026

From Guardant Health, Inc.

Via Business Wire

Guardant Health’s Shield Blood Test for Colorectal Cancer Screening Now Available for U.S. Military Members and Families

January 08, 2026

From Guardant Health, Inc.

Via Business Wire

BTIG's Top Stock Picks for H1 2026: Navigating the New 'Application' Era

January 02, 2026

Via MarketMinute

1 Growth Stock Set to Flourishand 2 We Avoid

January 01, 2026

Via StockStory

The Year-End Biotech Chill: Adaptive Biotechnologies Braces for J.P. Morgan Crucible Amid Market Sell-Off

December 30, 2025

Via MarketMinute

Guardant Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference

December 29, 2025

From Guardant Health, Inc.

Via Business Wire

Why a Top Biotech Holder Sold 115,000 Mirum Shares but Still Ended Up With $185 Million on the Line ↗

December 28, 2025

Via The Motley Fool

Q3 Earnings Roundup: Cardinal Health (NYSE:CAH) And The Rest Of The Healthcare Providers & Services Segment

December 17, 2025

Via StockStory

Q3 Rundown: The Ensign Group (NASDAQ:ENSG) Vs Other Healthcare Providers & Services Stocks

December 15, 2025

Via StockStory

Guardant Health Announces Collaboration with Trial Library to Increase Access to Cancer Clinical Trials Across the U.S.

December 11, 2025

From Guardant Health, Inc.

Via Business Wire

Guardant Health and Policlinico Gemelli Launch In-House Liquid Biopsy Testing Service in Italy

December 09, 2025

From Guardant Health, Inc.

Via Business Wire

3 Volatile Stocks Walking a Fine Line

December 07, 2025

Via StockStory

Guardant Health to Present 14 Abstracts Demonstrating the Power of Multiomic Liquid Biopsy Tests in Predicting Outcomes and Tailoring Treatment for Early and Metastatic Breast Cancer at the 2025 San Antonio Breast Cancer Symposium

December 05, 2025

From Guardant Health, Inc.

Via Business Wire

Frequently Asked Questions

Is Guardant Health, Inc. - Common Stock publicly traded?

Yes, Guardant Health, Inc. - Common Stock is publicly traded.

What exchange does Guardant Health, Inc. - Common Stock trade on?

Guardant Health, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Guardant Health, Inc. - Common Stock?

The ticker symbol for Guardant Health, Inc. - Common Stock is GH on the Nasdaq Stock Market

What is the current price of Guardant Health, Inc. - Common Stock?

The current price of Guardant Health, Inc. - Common Stock is 105.30

When was Guardant Health, Inc. - Common Stock last traded?

The last trade of Guardant Health, Inc. - Common Stock was at 02/13/26 10:04 AM ET

What is the market capitalization of Guardant Health, Inc. - Common Stock?

The market capitalization of Guardant Health, Inc. - Common Stock is 10.67B

How many shares of Guardant Health, Inc. - Common Stock are outstanding?

Guardant Health, Inc. - Common Stock has 11B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.